Pancreatic Cancer Research

ResearcherNational Taiwan UniversityNo recent work listed

Ting‐Chun Kuo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1960-1423; OpenAlex author ID A5044909048. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper

Papers 8

  1. Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report. Co-author DOI 10.3389/fimmu.2022.1077840↗
  2. C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin αv. Co-author DOI 10.1038/s41388-020-01594-4↗
  3. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2021.1973710↗
  4. Prospective comparison of (4S)-4-(3-18F-fluoropropyl)-L-glutamate versus 18F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocar… Co-author DOI 10.1007/s00259-018-4251-5↗
  5. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. Co-author DOI 10.1007/s00259-018-3960-0↗
  6. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. First author DOI 10.1038/s41388-018-0403-0↗
  7. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine… Co-author DOI 10.1371/journal.pone.0180628↗
  8. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. First author DOI 10.3748/wjg.v22.i32.7275↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shih‐Hung Yang · 6 shared papers, 2016–2022 · strength 0.67
  2. Yu‐Wen Tien · 7 shared papers, 2016–2021 · strength 0.66
  3. Bang‐Bin Chen · 3 shared papers, 2018–2022 · strength 0.41
  4. Ann‐Lii Cheng · 3 shared papers, 2016–2021 · strength 0.26
  5. Sung‐Hsin Kuo · 3 shared papers, 2016–2021 · strength 0.26
  6. Min‐Chuan Huang · 2 shared papers, 2018–2021 · strength 0.23
  7. Syue‐Ting Chen · 2 shared papers, 2018–2021 · strength 0.23
  8. Shang‐Hsuan Peng · 1 shared paper, 2022 · strength 0.20
  9. Kun‐Huei Yeh · 2 shared papers, 2016–2021 · strength 0.19
  10. Mei‐Fang Cheng · 2 shared papers, 2018–2019 · strength 0.17
  11. Jhe‐Cyuan Guo · 2 shared papers, 2016–2017 · strength 0.13
  12. Li‐Yuan Bai · 1 shared paper, 2021 · strength 0.13
  13. Yung‐Ming Jeng · 1 shared paper, 2019 · strength 0.09
  14. Tiffany Ting‐Fang Shih · 1 shared paper, 2018 · strength 0.08
  15. Yu‐Ting Chang · 1 shared paper, 2018 · strength 0.08
  16. Chih‐Horng Wu · 1 shared paper, 2018 · strength 0.08
  17. Ming‐Chu Chang · 1 shared paper, 2018 · strength 0.08
  18. Hsu Wu · 1 shared paper, 2016 · strength 0.06
  19. Chiun Hsu · 1 shared paper, 2016 · strength 0.06
  20. Chih‐Hung Hsu · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.